Key result
Dapagliflozin plus atorvastatin attenuates HIV-associated cardiac fibrosis by inhibiting platelet TGFβ1 signaling in mice.
Why the study?
Cardiovascular disease is a leading cause of morbidity in people with HIV, and while pitavastatin reduces atherosclerotic CVD, the impact of statin therapy on cardiac fibrosis driving HFpEF is unknown.
Do dapagliflozin and atorvastatin attenuate HIV-associated cardiac fibrosis in a mouse model?
Do dapagliflozin and atorvastatin attenuate HIV-associated cardiac fibrosis in a mouse model?
Answers are grounded in this paper and cite their sources.
In a preclinical mouse model, dapagliflozin and atorvastatin attenuate HIV-associated cardiac fibrosis by inhibiting platelet TGFβ1-induced signaling.
Cardiovascular disease (CVD) remains a leading cause of morbidity in people with HIV (PWH). While the REPRIEVE trial established that pitavastatin reduces atherosclerotic CVD, its impact on cardiac fibrosis—a primary driver of heart failure with preserved ejection fraction (HFpEF)—is unknown.
No takes yet. Share an insight, caveat, or question.
Ahamed et al. (2026) studied this question. Dapagliflozin and atorvastatin attenuated HIV-associated cardiac fibrosis in a mouse model by inhibiting platelet TGFβ1-induced signaling.
Synapse has enriched 10 related papers. Consider them for comparative context: